Loading...
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OABI’s FA Score shows that 1 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OABI’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).
OABI (@Biotechnology) experienced а 0.00% price change this week, while PRME (@Biotechnology) price change was +26.12% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.15%. For the same industry, the average monthly price growth was +4.69%, and the average quarterly price growth was +62.76%.
OABI is expected to report earnings on May 11, 2023.
PRME is expected to report earnings on Aug 05, 2024.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
OABI | PRME | OABI / PRME | |
Capitalization | 534M | 811M | 66% |
EBITDA | N/A | N/A | - |
Gain YTD | -26.418 | -23.702 | 111% |
P/E Ratio | N/A | N/A | - |
Revenue | N/A | N/A | - |
Total Cash | N/A | N/A | - |
Total Debt | N/A | N/A | - |
OABI | PRME | |
---|---|---|
RSI ODDS (%) | 1 day ago71% | 1 day ago90% |
Stochastic ODDS (%) | 1 day ago50% | 1 day ago90% |
Momentum ODDS (%) | 1 day ago43% | 1 day ago81% |
MACD ODDS (%) | 1 day ago34% | 1 day ago75% |
TrendWeek ODDS (%) | 1 day ago62% | 1 day ago66% |
TrendMonth ODDS (%) | 1 day ago72% | 1 day ago68% |
Advances ODDS (%) | 2 days ago63% | 1 day ago68% |
Declines ODDS (%) | 9 days ago75% | 11 days ago75% |
BollingerBands ODDS (%) | 4 days ago71% | 1 day ago90% |
Aroon ODDS (%) | 1 day ago78% | 1 day ago83% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
ACFOX | 56.13 | 0.75 | +1.35% |
American Century Focused Dynamic Gr Inv | |||
LQFLX | 12.46 | 0.12 | +0.97% |
Lord Abbett Focused Large Cap Value R3 | |||
ESMAX | 16.04 | 0.15 | +0.94% |
Invesco EQV Euro Small Company A | |||
AVEFX | 11.93 | 0.03 | +0.25% |
Ave Maria Bond | |||
PLFSX | 25.91 | N/A | N/A |
Principal Large Cap S&P 500 Index R4 |
A.I.dvisor indicates that over the last year, OABI has been loosely correlated with ABCL. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if OABI jumps, then ABCL could also see price increases.
Ticker / NAME | Correlation To OABI | 1D Price Change % | ||
---|---|---|---|---|
OABI | 100% | +0.89% | ||
ABCL - OABI | 43% Loosely correlated | -3.14% | ||
NTLA - OABI | 40% Loosely correlated | +1.90% | ||
LGND - OABI | 39% Loosely correlated | +0.56% | ||
TFFP - OABI | 38% Loosely correlated | +8.06% | ||
DNLI - OABI | 38% Loosely correlated | +5.62% | ||
More |
A.I.dvisor indicates that over the last year, PRME has been loosely correlated with BEAM. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then BEAM could also see price increases.
Ticker / NAME | Correlation To PRME | 1D Price Change % | ||
---|---|---|---|---|
PRME | 100% | +1.50% | ||
BEAM - PRME | 64% Loosely correlated | +1.26% | ||
NTLA - PRME | 63% Loosely correlated | +1.90% | ||
XNCR - PRME | 53% Loosely correlated | +4.57% | ||
RLAY - PRME | 53% Loosely correlated | +6.84% | ||
EDIT - PRME | 50% Loosely correlated | +5.63% | ||
More |